BPCE
SRPT icon

Bank Pictet & Cie (Europe)’s Sarepta Therapeutics SRPT Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,467
Closed -$300K – 203
2024
Q4 		$300K Sell
2,467
-360
-13% -$44.1K 0.01% 145
2024
Q3 		$353K Buy
2,827
+613
+28% +$84.7K 0.01% 129
2024
Q2 		$350K Buy
+2,214
New +$284K 0.01% 129

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s SRPT Position: Q1 2025 in Review

Bank Pictet & Cie (Europe) sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,467 shares — an estimated $300K sold.

Bank Pictet & Cie (Europe) first reported a position in SRPT in Q2 2024 and held it in 3 quarters. The position peaked at $353K in Q3 2024. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Bank Pictet & Cie (Europe) reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 2,467 Sarepta Therapeutics shares in Q1 2025, an estimated $300K.
  • Bank Pictet & Cie (Europe) first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 3 quarters.
  • Bank Pictet & Cie (Europe)'s Sarepta Therapeutics position peaked at $353K in Q3 2024.
  • 431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q1 2025, filed 17 Apr 2025.